Clinical Trials

Numerous clinical trials evaluate amfebutamone (bupropion) across Phase 1 through Phase 4, encompassing completed, recruiting, terminated, and withdrawn studies. Key indications under investigation include major depressive disorder, tobacco use disorder, morbid obesity, schizophrenia, and drug interactions in advanced solid tumors. Sponsored by academic institutions, medical centers, and pharmaceutical companies, these trials assess both monotherapies and combination regimens across diverse therapeutic areas.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07398404 NOT_YET_RECRUITING
Obesity; Smoking Cessation; Bariatric Surgery Patients
Medical University of South Carolina
 2026-09-01 PHASE1; PHASE2
NCT07714200 NOT_YET_RECRUITING
Tobacco Use Disorder
VA Office of Research and Development
 2027-03-01
NCT02129751 NOT_YET_RECRUITING
Major Depressive Disorder
Bausch Health Americas, Inc.
 2026-06 PHASE4
NCT06098079 ACTIVE_NOT_RECRUITING
Obesity
Currax Pharmaceuticals
 2024-01-03 PHASE4
NCT04604509 RECRUITING
Cigarette Smoking-Related Carcinoma
M.D. Anderson Cancer Center
 2020-08-04 PHASE4
NCT07596212 NOT_YET_RECRUITING
Early-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer
University of Illinois at Chicago
 2026-09 PHASE1; PHASE2
NCT05973786 RECRUITING
Bipolar Depression
Dr. Inge Winter
 2025-02-11 PHASE3
NCT05603104 RECRUITING
Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression
Dr. Inge Winter
 2025-04-27 PHASE3
NCT06620562 RECRUITING
Obesity; Drug; Obesity, Morbid
Laval University
 2025-06-04 PHASE4
NCT07213466 RECRUITING
Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1
Mayo Clinic
 2026-01-19 PHASE4
NCT07224087 NOT_YET_RECRUITING
Obesity; Smoking Cessation; Bariatric Surgery Patients
Medical University of South Carolina
 2026-09-01 PHASE1
NCT07766655 RECRUITING
Smoking Cessation
Axsome Therapeutics, Inc.
 2026-08 PHASE3
NCT06845345 ENROLLING_BY_INVITATION
Diabetes Mellitus, Type 2; Liver Fibrosis; Liver Steatoses; Hepatic Steatosis; Hepatic Fibrosis; Overweight or Obesity; MASLD; MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Cardio-metabolic Risk; Cardio-metabolic Health; Hypertension; Dyslipidaemia
Carmen Dietvorst
 2025-04-14 PHASE4
NCT05919797 RECRUITING
Obesity
Columbia University
 2023-06-08 PHASE4
NCT05273996 ACTIVE_NOT_RECRUITING
Major Depressive Disorder; Neuroticism; Cognitive Change; Stress
David Steffens
 2021-09-28 PHASE4
NCT06854614 ACTIVE_NOT_RECRUITING
Obesity
The Cleveland Clinic
 2025-03-01 PHASE4
NCT07584434 RECRUITING
Narcolepsy Type 1 (NT1)
Vertex Pharmaceuticals Incorporated
 2026-05-21 PHASE1
NCT05732272 RECRUITING
Smoking Cessation
University of Kansas Medical Center
 2023-02-28 PHASE3
NCT05157698 ACTIVE_NOT_RECRUITING
Obesity
Yale University
 2022-01-13 PHASE3
NCT06881485 RECRUITING
Weight Regain Post Bariatric Surgery; Obesity (Disorder)
Universitaire Ziekenhuizen KU Leuven
 2025-01-20
NCT07269873 RECRUITING
Healthy Adult Male and Female Volunteers
BioCorRx Pharmaceuticals Inc
 2026-03-16 PHASE1
NCT06675851 RECRUITING
Major Depressive Disorder (MDD)
Medical University of Vienna
 2022-12-01 PHASE4
NCT06609343 NOT_YET_RECRUITING
End Stage Renal Disease; Fatigue
The University of Texas Health Science Center at San Antonio
 2026-08-24 PHASE1; PHASE2
NCT05646862 RECRUITING
Breast Cancer
Hoffmann-La Roche
 2023-06-07 PHASE3
NCT07766369 NOT_YET_RECRUITING
Healthy Volunteers
Eisai Inc.
 2026-08-12 PHASE1
NCT06233799 ACTIVE_NOT_RECRUITING
Methamphetamine-dependence; Methamphetamine Abuse
National Institute on Drug Abuse (NIDA)
 2024-07-01 PHASE3
NCT06958692 RECRUITING
Major Depressive Disorder (MDD)
CSPC Ouyi Pharmaceutical Co., Ltd.
 2025-04-11 PHASE3
NCT04422652 ACTIVE_NOT_RECRUITING
Chronic Kidney Diseases; Major Depressive Disorder; End Stage Kidney Disease (ESRD)
Stony Brook University
 2020-09-24 PHASE2
NCT04098874 COMPLETED
Postpartum Smoking Relapse
University of Minnesota
 2020-01-01 PHASE4
NCT07171112 WITHDRAWN
Pancreatitis, Chronic; Pancreatitis, Acute; Recurrent Acute Pancreatitis; Smoking (Tobacco) Addiction
Mayo Clinic
 2025-11-06 PHASE2
NCT07523048 RECRUITING
Major Depressive Disorder (MDD)
Roger McIntyre
 2025-11-21 PHASE2
NCT04605081 COMPLETED
Loss-of-Control Eating; Obesity/Overweight
Yale University
 2022-06-10 PHASE2; PHASE3
NCT04599478 COMPLETED
Loss-of-control Eating; Obesity/Overweight
Yale University
 2021-06-29 PHASE2; PHASE3
NCT03996265 ACTIVE_NOT_RECRUITING
Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm
University of Rochester NCORP Research Base
 2019-06-27 PHASE3
NCT07259330 COMPLETED
Healthy
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
 2025-10-27 PHASE1
NCT06223880 RECRUITING
Major Depressive Disorder
Axsome Therapeutics, Inc.
 2023-12-27 PHASE4
NCT07223671 COMPLETED
Healthy Volunteers
Bristol-Myers Squibb
 2025-12-31 PHASE1
NCT06605703 COMPLETED
Obesity; Overweight
WW International Inc
 2024-09-18 PHASE4
NCT04634071 COMPLETED
Smoking Cessation; Cancer, Treatment-Related
Joseph Valentino, MD
 2021-01-12 PHASE2
NCT07235748 COMPLETED
Healthy Adult Participants
Institut de Recherches Internationales Servier (I.R.I.S.)
 2025-10-07 PHASE1
NCT06564441 COMPLETED
Overweight; Obesity
Boehringer Ingelheim
 2024-10-01 PHASE1
NCT06957223 COMPLETED
Major Depressive Disorder (MDD)
Asad Ullah Jan
 2025-05-06
NCT03978442 COMPLETED
Smoking; Stress Disorders, Post-Traumatic
VA Office of Research and Development
 2019-11-07 PHASE4
NCT05537584 COMPLETED
Major Depressive Disorder
Mclean Hospital
 2022-09-30 PHASE4
NCT03950427 COMPLETED
Smoking Cessation; Smoking, Tobacco; Mental Illness; Tobacco Use Disorder
University of California, San Francisco
 2019-07-08 PHASE4
NCT07049107 COMPLETED
Health Volunteer
Jiangsu HengRui Medicine Co., Ltd.
 2025-06-23 PHASE1
NCT06973005 COMPLETED
Advanced Chronic Liver Disease; Healthy Participants
AstraZeneca
 2025-05-08 PHASE1
NCT05976646 COMPLETED
Addiction; Opioid Use; Substance Use Disorders; Opioid Use Disorder
Virginia Commonwealth University
 2023-09-18 PHASE1; PHASE2
NCT05205811 COMPLETED
Smoking Cessation
Rose Research Center, LLC
 2021-12-14 PHASE3
NCT06679413 COMPLETED
Healthy Study Participants
UCB BIOSCIENCES, Inc.
 2024-12-04 PHASE1
NCT04902625 UNKNOWN
Obesity, Morbid; Bariatric Surgery Candidate; Medication Persistence
Zuyderland Medisch Centrum
 2023-03-21 PHASE4
NCT06736509 TERMINATED
Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor
Axsome Therapeutics, Inc.
 2024-11-21 PHASE3
NCT06254001 UNKNOWN
Tobacco Smoking; Tobacco Withdrawal; Nicotine Addiction; Nicotine Withdrawal; Nicotine Replacement Therapy
National Institute of Respiratory Diseases, Mexico
 2024-01-15 PHASE4
NCT04553263 WITHDRAWN
Stimulant Use; Relapse; Cognitive Function; ADHD
University of California, Los Angeles
 2023-06-11 EARLY_PHASE1
NCT06566794 COMPLETED
Drug Interaction
Helsinki University Central Hospital
 2024-08-22
NCT05351606 COMPLETED
Tobacco Use Cessation; Tobacco Use
University of California, San Francisco
 2023-05-16 PHASE4
NCT03946111 COMPLETED
Binge-Eating Disorder; Obesity
Yale University
 2019-08-07 PHASE2; PHASE3
NCT06374290 TERMINATED
Smoking Cessation
The University of Texas Health Science Center, Houston
 2024-07-16 PHASE1
NCT04947553 COMPLETED
Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor
Axsome Therapeutics, Inc.
 2021-06-17 PHASE3
NCT05579249 COMPLETED
Obesity
Novo Nordisk A/S
 2023-01-19 PHASE4
NCT04490057 COMPLETED
Tobacco Use Cessation
Yale University
 2020-07-27 PHASE4
NCT06367153 COMPLETED
Healthy
Boehringer Ingelheim
 2024-05-15 PHASE1
NCT04694846 COMPLETED
Lung Non-Small Cell Carcinoma; Head and Neck Squamous Cell Carcinoma
Thomas Jefferson University
 2020-08-19
NCT05531591 COMPLETED
Depression; Dementia; Mild Cognitive Impairment; Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression
Centre for Addiction and Mental Health
 2019-08-01 PHASE4
NCT05420350 UNKNOWN
Meniere Disease; Ménière's Vertigo; Vertigo, Intermittent; Vertigo, Aural
Dent Neuroscience Research Center
 2020-12-16 PHASE2
NCT04589130 UNKNOWN
Obesity
St. Joseph's Healthcare Hamilton
 2021-02-01 PHASE4
NCT04587843 UNKNOWN
Obesity
St. Joseph's Healthcare Hamilton
 2021-04-01 PHASE4
NCT05981365 COMPLETED
Sickle Cell Disease
Pfizer
 2023-04-17 PHASE1
NCT05932277 COMPLETED
Healthy Volunteers
Bristol-Myers Squibb
 2023-06-29 PHASE1
NCT03342027 COMPLETED
HIV; Smoking Cessation
University of Maryland, Baltimore
 2020-08-01 PHASE3
NCT03326128 TERMINATED
Smoking Cessation; Smoking, Tobacco; Smoking (Tobacco) Addiction; Cessation, Tobacco; Cigarette Smoking
University of Southern California
 2021-09-01 PHASE2
NCT04388189 WITHDRAWN
Major Depressive Disorder
Alto Neuroscience
 2020-10-15 PHASE4
NCT04902625 Recruiting
Obesity Morbid|Bariatric Surgery Candidate|Medication Persistence
Zuyderland Medisch Centrum|Nederlandse Obesitas Kliniek
 2023-03-21 Phase 4
NCT03623711 UNKNOWN
Major Depressive Disorder; Depression, Unipolar
Yuqi Cheng
 2018-08-01 EARLY_PHASE1
NCT04167306 COMPLETED
Alcohol Use Disorder; Alcoholism; Alcohol Dependence
Vastra Gotaland Region
 2019-03-04 PHASE2
NCT04718740 COMPLETED
Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
 2021-06-25 PHASE1
NCT04575194 UNKNOWN
Obesity; Blood Pressure
National and Kapodistrian University of Athens
 2020-09-08 PHASE4
NCT04399395 WITHDRAWN
Obesity
Oslo University Hospital
 2020-11-01 PHASE4
NCT04531176 TERMINATED
Type 2 Diabetes; Obesity
The Cleveland Clinic
 2020-09-01 PHASE4
NCT04352101 COMPLETED
Major Depression
Emory University
 2020-09-23 PHASE4
NCT03864042 COMPLETED
Advanced Solid Tumors; Metastatic Melanoma
Pfizer
 2018-01-02 PHASE1
NCT03374956 COMPLETED
Obesity
Mayo Clinic
 2017-12-11 PHASE3
NCT03539900 COMPLETED
Binge-Eating Disorder
Yale University
 2018-04-17 PHASE2; PHASE3
NCT03362099 COMPLETED
Smoking Cessation; Genetic Predisposition
University of Sao Paulo General Hospital
 2016-11-01 PHASE4
NCT03993457 TERMINATED
Depression
University of Texas Southwestern Medical Center
 2019-07-23 PHASE4
NCT04634669 TERMINATED
Treatment Resistant Depression; Major Depressive Disorder
Axsome Therapeutics, Inc.
 2020-09-23 PHASE2
NCT03047005 COMPLETED
Binge-Eating Disorder; Obesity
Yale University
 2017-08-28 PHASE2; PHASE3
NCT01965405 UNKNOWN
HIV; AIDS; Nicotine Dependence
Wayne State University
 2013-08
NCT03897439 COMPLETED
Smoking Cessation
University of Kansas Medical Center
 2019-05-01 PHASE3
NCT04899674 COMPLETED
Healthy
Boehringer Ingelheim
 2021-06-30 PHASE1
NCT03852160 WITHDRAWN
Depressive Disorder, Treatment-Resistant
Janssen-Cilag International NV
 2019-12-01 PHASE3
NCT03045341 COMPLETED
Binge-eating Disorder; Obesity
Yale University
 2017-02-27 PHASE2; PHASE3
NCT04135937 COMPLETED
Human Immunodeficiency Virus; Smoking
VA Office of Research and Development
 2019-11-18 PHASE4
NCT04971291 UNKNOWN
Major Depressive Disorder; Treatment Resistant Depression
Axsome Therapeutics, Inc.
 2021-04-14 PHASE2
NCT04464577 WITHDRAWN
Healthy Participants
Bristol-Myers Squibb
 2021-04-01 PHASE1
NCT04388319 COMPLETED
Smoking Cessation
Rose Research Center, LLC
 2020-05-27 PHASE3
NCT04718740 Completed
Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co. Ltd.
 2021-06-25 Phase 1
NCT04526210 COMPLETED
Wilson Disease
Alexion Pharmaceuticals, Inc.
 2020-10-21 PHASE1
NCT04457180 COMPLETED
Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
 2020-11-16 PHASE1
NCT04713254 COMPLETED
Healthy
H. Lundbeck A/S
 2020-12-08 PHASE1
NCT04757532 COMPLETED
Healthy Volunteers
Parc de Salut Mar
 2020-12-03 PHASE1
NCT03180294 COMPLETED
Breast Carcinoma; Cervical Carcinoma; Ovarian Carcinoma; Postmenopausal; Uterine Corpus Cancer; Vaginal Carcinoma; Vulvar Carcinoma
NRG Oncology
 2017-05-31 PHASE2
NCT04664725 UNKNOWN
Prostate Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
 2020-06-01 PHASE1
NCT04643249 COMPLETED
Mitochondrial Disease
Abliva AB
 2020-11-10 PHASE1
NCT04039022 COMPLETED
Major Depressive Disorder; Treatment Resistant Depression; Depression
Axsome Therapeutics, Inc.
 2019-07-08 PHASE3
NCT02960763 COMPLETED
Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression
Washington University School of Medicine
 2017-02-24 PHASE4
NCT02332291 COMPLETED
Major Depressive Disorder
Vanderbilt University Medical Center
 2015-04 PHASE4
NCT00943618 COMPLETED
Smoking Cessation
M.D. Anderson Cancer Center
 2010-05-17 PHASE3
NCT02111798 COMPLETED
Substance Abuse; Cocaine Dependence
Johns Hopkins University
 2014-07 PHASE2; PHASE3
NCT03226522 COMPLETED
Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Axsome Therapeutics, Inc.
 2017-07-13 PHASE2; PHASE3
NCT00958633 TERMINATED
Bipolar I Disorder
University of British Columbia
 2010-11 PHASE3
NCT02741791 COMPLETED
Treatment Resistant Major Depressive Disorder
Axsome Therapeutics, Inc.
 2016-03 PHASE3
NCT02995915 COMPLETED
Smoking Cessation; Alcohol Drinking
Duke University
 2016-11 PHASE4
NCT05160090 COMPLETED
Bioequivalence
Alembic Pharmaceuticals Ltd.
 2020-01-18 PHASE1
NCT02188459 COMPLETED
Smoking; Nicotine Dependence
Henry Kranzler
 2014-10-30 PHASE2
NCT03148509 UNKNOWN
Diagnosis and Treatment of Depression
Peking University
 2017-06-01 PHASE4
NCT00507728 COMPLETED
Tobacco Use Disorder; Smoking Cessation
M.D. Anderson Cancer Center
 2005-12-08 PHASE2; PHASE3
NCT03219008 UNKNOWN
Depressive Disorder
Shanghai Mental Health Center
 2017-08-01 PHASE4
NCT04709094 COMPLETED
Healthy
Alexion Pharmaceuticals, Inc.
 2019-07-28 PHASE1
NCT04848246 COMPLETED
Tuberculosis, Pulmonary
Dow University of Health Sciences
 2017-11-06
NCT02994082 UNKNOWN
Smokeless Tobacco; Nicotine Dependence
Mark Vander Weg
 2016-12
NCT03169244 COMPLETED
Alcohol Abuse
University of North Carolina, Chapel Hill
 2017-09-04 PHASE2
NCT03078075 COMPLETED
Methamphetamine Use Disorder
University of Texas Southwestern Medical Center
 2017-05-05 PHASE3
NCT02048917 COMPLETED
Lung Cancer; Head and Neck Cancer
University of Kentucky
 2014-07-22 PHASE1
NCT03420469 COMPLETED
Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
Indiana University
 2018-06-05 EARLY_PHASE1
NCT03471767 COMPLETED
Smoking Cessation; Smoking, Cigarette; Nicotine Dependence
James Davis
 2018-03-25 PHASE2
NCT02420015 COMPLETED
Schizophrenia; Cigarette Smoking
Duke University
 2017-03-27 PHASE4
NCT03595579 COMPLETED
Major Depressive Disorder
Axsome Therapeutics, Inc.
 2018-05-30 PHASE2
NCT03553173 COMPLETED
Smoking Cessation; Health Behavior; Lifestyle-related Condition
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
 2016-10-24
NCT02582008 TERMINATED
Current Smoker; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma
Wake Forest University Health Sciences
 2016-01 EARLY_PHASE1
NCT03132571 TERMINATED
Schizophrenia; Diabetes Mellitus, Type 2; Obesity
Yale University
 2017-06-01 PHASE2
NCT03581630 COMPLETED
Breast Cancer; Obesity; Overweight
Gangnam Severance Hospital
 2017-07-29
NCT03301207 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
 2017-10-20 PHASE1
NCT03199339 COMPLETED
Tuberculosis; Tuberculosis, Pulmonary
Global Alliance for TB Drug Development
 2017-08-29 PHASE1
NCT02736474 COMPLETED
Obese; Cigarette-smoking; Schizophrenia
Shanghai Mental Health Center
 2016-05 PHASE4
NCT03126682 COMPLETED
MDD
Duke University
 2017-08-25 PHASE4
NCT02245308 COMPLETED
Tobacco Use Disorder; Homelessness
VA Office of Research and Development
 2014-10-01 PHASE4
NCT02238977 TERMINATED
Major Depression; End Stage Renal Disease
University of Arkansas
 2016-03-31 PHASE4
NCT01892813 UNKNOWN
Nicotine Dependence; Tobacco Use
Mark Vander Weg
 2013-07 PHASE3
NCT02842073 COMPLETED
Binge Drinking
University of North Carolina, Chapel Hill
 2016-11-01 PHASE2
NCT01739192 COMPLETED
Cocaine Use Disorders
Craig Rush
 2013-01 EARLY_PHASE1
NCT02593396 COMPLETED
Sexual Dysfunctions, Psychological; Hypoactive Sexual Desire Disorder; Erectile Dysfunctions
University of Malaya
 2015-12 PHASE2
NCT02616315 WITHDRAWN
Weight Regain Post Bariatric Surgery
Takeda
 2016-02 PHASE4
NCT01901848 COMPLETED
Stress Disorders, Post-Traumatic; Smoking
VA Office of Research and Development
 2013-12-11 PHASE2; PHASE3
NCT03234699 COMPLETED
Healthy
SK Life Science, Inc.
 2017-02-22 PHASE1
NCT02873754 COMPLETED
Smoking
Duke University
 2017-01
NCT02374567 TERMINATED
Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
Hannover Medical School
 2015-01 PHASE3
NCT02869451 COMPLETED
Cigarette Smoking; Marijuana Abuse
Duke University
 2016-08
NCT03058419 COMPLETED
Healthy
Janssen Research & Development, LLC
 2017-03-14 PHASE1
NCT02146911 COMPLETED
Tobacco Use Disorder; Nicotine Dependence
Centre for Addiction and Mental Health
 2014-05-01
NCT01390246 COMPLETED
Pregnancy Related; Tobacco Use Disorder
The University of Texas Medical Branch, Galveston
 2011-07 PHASE4
NCT02078180 COMPLETED
Depression
University of Michigan
 2014-04 PHASE4
NCT02191397 COMPLETED
Depressive Disorder, Major
GlaxoSmithKline
 2015-02-10 PHASE3
NCT03227679 COMPLETED
Tobacco Use; Tobacco Use Cessation
Vanderbilt University Medical Center
 2016-05-18
NCT00580853 COMPLETED
Smoking Lapse Behavior
Yale University
 2007-04 PHASE2
NCT02317744 COMPLETED
Binge Eating Disorder
Yale University
 2014-12
NCT02209597 COMPLETED
Major Depressive Disorder
Washington University School of Medicine
 2014-06-25 PHASE4
NCT01769768 COMPLETED
Advanced Solid Tumor
Novartis Pharmaceuticals
 2013-04 PHASE1
NCT02735603 COMPLETED
Heart Repolarization
Orexigen Therapeutics, Inc
 2016-04 PHASE1
NCT02162862 COMPLETED
Sleep Disturbance; Fatigue; Inflammatory Bowel Disease
Eva Szigethy
 2013-07 PHASE4
NCT02698553 COMPLETED
Depressive Disorder, Major
GlaxoSmithKline
 2016-05-23 PHASE1
NCT02676375 COMPLETED
Smoking Cessation; Schizophrenia
Brentwood Biomedical Research Institute
 2014-01 PHASE4
NCT02638129 TERMINATED
Obesity; Cardiovascular Diseases
Orexigen Therapeutics, Inc
 2016-01 PHASE4
NCT02745912 COMPLETED
Healthy Subjects
Orexigen Therapeutics, Inc
 2016-04 PHASE1
NCT02401256 COMPLETED
Healthy
Indiana University
 2013-07 PHASE4
NCT02104128 COMPLETED
Depression
University of Oxford
 2014-01
NCT01407094 COMPLETED
Depression
University of Texas Southwestern Medical Center
 2011-07-29 PHASE2
NCT02568176 COMPLETED
Healthy
Janssen Research & Development, LLC
 2015-10 PHASE1
NCT03278938 WITHDRAWN
Depressive Illness
New York State Psychiatric Institute
 2012-06-29 PHASE4
NCT01942187 WITHDRAWN
Major Depressive Disorder; Dysthymic Disorder; Depressive Disorder Not Otherwise Specified (NOS)
New York State Psychiatric Institute
 2013-08 PHASE4
NCT01015170 COMPLETED
Cigarette Smoking; Nicotine Addiction; Smoking Cessation
Centre for Addiction and Mental Health
 2009-10 PHASE4
NCT01990079 COMPLETED
PTSD; Smoking
Duke University
 2013-12
NCT01421342 COMPLETED
Major Depressive Disorder
VA Office of Research and Development
 2012-12 PHASE3
NCT01601704 TERMINATED
Obesity; Overweight
Orexigen Therapeutics, Inc
 2012-06 PHASE3
NCT01574703 COMPLETED
Smoking Cessation
Pfizer
 2012-05 PHASE4
NCT00926835 TERMINATED
Major Depressive Disorder
Ministry of Health & Welfare, Korea
 2009-05 PHASE4
NCT02391688 COMPLETED
Drug Interaction
Jules Desmeules
 2014-11 PHASE1
NCT02369172 COMPLETED
Healthy
Maruho Europe Limited
 2015-02 PHASE1
NCT01583023 UNKNOWN
Bipolar Disorder
McGill University Health Centre/Research Institute of the McGill University Health Centre
 2014-04 PHASE4
NCT01330043 COMPLETED
Smoking Cessation
Stanford University
 2010-03 PHASE4
NCT01748955 COMPLETED
Depression; Suicidal Ideation
New York State Psychiatric Institute
 2010-06 PHASE4
NCT02305901 COMPLETED
Healthy
Boehringer Ingelheim
 2014-12 PHASE1
NCT02173886 COMPLETED
Roux en Y Gastric Bypass
North Dakota State University
 2014-06 PHASE4
NCT01982643 COMPLETED
Methamphetamine Use Disorder
Walter Ling
 2013-11 PHASE1; PHASE2
NCT01456936 COMPLETED
Smoking Cessation
Pfizer
 2011-11 PHASE4
NCT01806779 COMPLETED
Nicotine Dependence
Duke University
 2013-03 PHASE2
NCT02259179 COMPLETED
Healthy
Orexigen Therapeutics, Inc
 2014-09 PHASE1
NCT01857596 COMPLETED
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined); Sexual Interest/Arousal Disorder (DSM-5 Defined)
S1 Biopharma, Inc.
 2013-04 PHASE1; PHASE2
NCT01764867 UNKNOWN
Major Depressive Disorder
Shanghai Mental Health Center
 2012-06 PHASE4
NCT01789710 COMPLETED
Smoking; Homeless Persons
Duke University
 2013-01
NCT01764386 COMPLETED
Obesity; Overweight
Orexigen Therapeutics, Inc
 2013-02 PHASE3
NCT01896349 UNKNOWN
Treatment Resistant Depression
Hospital de Clinicas de Porto Alegre
 2013-04
NCT01047254 COMPLETED
Apathy in Dementia
University Hospital, Bonn
 2010-01 PHASE3
NCT01914965 COMPLETED
Apathy; Huntington's Disease
Charite University, Berlin, Germany
 2012-06 PHASE2
NCT02085967 COMPLETED
Healthy Subjects
Eisai Inc.
 2014-02 PHASE1
NCT00106197 UNKNOWN
Depression
Uma Rao
 2004-06 PHASE4
NCT02744417 COMPLETED
Periodontitis
Claudio Mendes Pannuti
 2010-08
NCT01219673 TERMINATED
Head And Neck Cancer
M.D. Anderson Cancer Center
 2013-03 PHASE1; PHASE2
NCT01406223 COMPLETED
Nicotine Dependence
Duke University
 2011-07 PHASE3
NCT01560507 TERMINATED
Cigarette Smoking; Nicotine Dependence
Duke University
 2012-05 PHASE2; PHASE3
NCT01592695 COMPLETED
Cigarette Smoking
Iowa City Veterans Affairs Medical Center
 2012-06 PHASE2
NCT00936299 COMPLETED
Attention Deficit Hyperactivity Disorder; Nicotine Dependence; Cannabis Use Disorder
University of Colorado, Denver
 2009-01 PHASE4
NCT01771874 COMPLETED
Healthy; Substance-related Disorders
University Hospital, Basel, Switzerland
 2013-01 PHASE1
NCT00531518 COMPLETED
Schizophrenia; Bipolar Disorder; Depression; Psychotic Disorders
MaineHealth
 2007-10
NCT00178828 COMPLETED
Depression
Vanderbilt University Medical Center
 2002-10 PHASE4
NCT00935818 COMPLETED
Smoking
Mayo Clinic
 2009-09 PHASE2; PHASE3
NCT01303861 COMPLETED
Nicotine Dependence
Duke University
 2011-03 PHASE3
NCT00625131 COMPLETED
Stress Disorders, Posttraumatic; Tobacco Use Disorder
US Department of Veterans Affairs
 2008-05 EARLY_PHASE1
NCT01716221 COMPLETED
Friedreich Ataxia
University of Colorado, Denver
 2012-10 PHASE4
NCT01048944 COMPLETED
Nicotine Dependence
Southern Illinois University Carbondale
 2005-06 PHASE4
NCT00833443 COMPLETED
Methamphetamine; Amphetamine Dependence; Pharmacogenetics; Methamphetamine Dependence; Substance Abuse
University of California, Los Angeles
 2009-01 PHASE2
NCT01286402 COMPLETED
Smoking Cessation
The University of Texas Health Science Center, Houston
 2011-04 PHASE2
NCT01111149 COMPLETED
Schizophrenia; Smoking Cessation
University of Minnesota
 2009-12 PHASE2
NCT01635972 COMPLETED
Pharmacokinetics of Isavuconazole; Pharmacokinetics of Bupropion; Healthy Volunteers
Astellas Pharma Global Development, Inc.
 2012-06 PHASE1
NCT00396669 UNKNOWN
Tobacco Use Disorder
Hadassah Medical Organization
 2007-07
NCT01359930 COMPLETED
Methamphetamine Dependence
National Institute on Drug Abuse (NIDA)
 2011-08 PHASE1
NCT00917059 COMPLETED
Depression
University of California, Los Angeles
 2009-05 PHASE4
NCT01032018 COMPLETED
Acute Coronary Syndrome; Depression
Columbia University
 2010-01 PHASE1; PHASE2
NCT00994448 COMPLETED
Adolescent Methamphetamine Abuse
University of California, Los Angeles
 2009-10 PHASE2
NCT01023659 COMPLETED
Tobacco Use Disorder; Smoking; Smoking Cessation
Centre for Addiction and Mental Health
 2010-04 PHASE4
NCT00404755 COMPLETED
Major Depressive Disorder; Dysthymia
New York State Psychiatric Institute
 2006-07 PHASE4
NCT01477931 COMPLETED
Depressive Disorder, Major
Chi-Un Pae
 2010-11 PHASE4
NCT00894166 COMPLETED
Smoking Cessation
Duke University
 2009-05 PHASE3
NCT00519428 COMPLETED
Major Depressive Disorder
New York State Psychiatric Institute
 2007-08 PHASE4
NCT00687713 COMPLETED
Methamphetamine Dependence
National Institute on Drug Abuse (NIDA)
 2008-05 PHASE2
NCT00414167 COMPLETED
Binge Eating Disorder; Obesity
Yale University
 2005-12 PHASE2; PHASE3
NCT01541475 COMPLETED
Major Depressive Disorder
Ewha Womans University
 2009-03 PHASE4
NCT00504413 UNKNOWN
Substance-Related Disorders
University of Washington
 2007-07 PHASE1
NCT00819078 UNKNOWN
Smoking; Smoking Cessation
Geha Mental Health Center
 2009-01
NCT00129272 COMPLETED
Tobacco Use Cessation; Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)
 2004-05 PHASE2
NCT00449007 TERMINATED
Depression; Alcoholism; Suicidal Behavior
New York State Psychiatric Institute
 2006-02 PHASE4
NCT00440115 COMPLETED
Smoking Cessation
University of Kansas Medical Center
 2009-06 PHASE3
NCT00749658 COMPLETED
Nicotine Dependence; Nicotine Withdrawal
University of Minnesota
 2008-11 PHASE2; PHASE3
NCT00332644 COMPLETED
Nicotine Dependence
University of Wisconsin, Madison
 2004-09 PHASE4
NCT00612807 COMPLETED
Major Depressive Disorder; Partner Relational Disorder (V61.10)
Duke University
 2006-07 PHASE1; PHASE2
NCT00711477 COMPLETED
Obesity
Orexigen Therapeutics, Inc
 2008-09 PHASE2
NCT00666978 COMPLETED
Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder
Lisa Sanderson Cox, PhD
 2007-12 PHASE4
NCT00689611 COMPLETED
Acute Coronary Syndrome; Myocardial Infarction; Smoking
Mark Eisenberg
 2005-12 PHASE3
NCT00572234 COMPLETED
Methamphetamine Use Disorder
University of Nebraska
 2007-08-31
NCT00419731 UNKNOWN
Tobacco Use Disorder
University of Minnesota
 2006-11 PHASE2; PHASE3
NCT00304707 COMPLETED
Smoking Cessation; Alcohol-Related Disorders
National Institute on Drug Abuse (NIDA)
 2005-04 PHASE3
NCT00125957 COMPLETED
Depression; Major Depressive Disorder; Unipolar Depression
Mclean Hospital
 2005-08 PHASE3
NCT00429169 TERMINATED
Depression
New York State Psychiatric Institute
 2004-06 PHASE4
NCT00006170 COMPLETED
Tobacco Use Disorder
University of Pittsburgh
 2000-09 PHASE4
NCT00590863 COMPLETED
Major Depressive Disorder
National Institute of Mental Health (NIMH)
 2008-03 PHASE4
NCT00624858 COMPLETED
Depression
Orexigen Therapeutics, Inc
 2008-01 PHASE2
NCT00296647 COMPLETED
Tobacco Dependence
University of Wisconsin, Madison
 2004-09 PHASE4
NCT00330187 COMPLETED
Nicotine Dependence; Nicotine Use Disorder
Medical University of South Carolina
 2004-03 PHASE2
NCT00621517 COMPLETED
Restless Legs Syndrome
East Tennessee State University
 2008-02 PHASE2; PHASE3
NCT00567255 COMPLETED
Obesity; Overweight
Orexigen Therapeutics, Inc
 2007-12 PHASE3
NCT00474630 COMPLETED
Obesity; Overweight; Diabetes Mellitus, Type 2
Orexigen Therapeutics, Inc
 2007-05 PHASE3
NCT00136747 COMPLETED
Tobacco Use Disorder
New York State Psychiatric Institute
 2004-01 PHASE1
NCT00532779 COMPLETED
Obesity; Overweight
Orexigen Therapeutics, Inc
 2007-10 PHASE3
NCT00132821 COMPLETED
Tobacco Use Cessation; Sleep Disorders
National Institute on Drug Abuse (NIDA)
 2005-08 PHASE4
NCT00136786 COMPLETED
Tobacco Use Disorder
New York State Psychiatric Institute
 2006-12 PHASE1
NCT00709371 COMPLETED
Obesity
Orexigen Therapeutics, Inc
 2008-07 PHASE2
NCT00086385 COMPLETED
Tobacco Use Disorder
University of California, San Francisco
 2001-09 PHASE3
NCT00846339 COMPLETED
Smoking
Seoul National University Hospital
 2008-11 PHASE4
NCT00136760 COMPLETED
Schizophrenia and Disorders With Psychotic Features; Tobacco Use Disorder
Brown University
 2003-09 PHASE2
NCT00511134 TERMINATED
Insomnia; Nicotine Dependence
Yale University
 2007-04 PHASE4
NCT00308763 COMPLETED
Tobacco Use Disorder
University of Tennessee
 2004-01
NCT00456521 COMPLETED
Obesity; Overweight
Orexigen Therapeutics, Inc
 2007-03 PHASE3
NCT00320697 COMPLETED
Schizophrenia; Schizoaffective Disorder; Smokers
North Suffolk Mental Health Association
 2006-04 PHASE4
NCT00563563 COMPLETED
Nicotine Dependence; Overweight; Obesity
Orexigen Therapeutics, Inc
 2007-10 PHASE2
NCT00692510 COMPLETED
Metabolism; Alzheimer's Disease
AstraZeneca
 2007-11 PHASE1
NCT00587769 COMPLETED
Smoking; Tobacco Use Disorder
Mayo Clinic
 2007-07 PHASE3
NCT00225251 COMPLETED
Dysthymic Disorder
St. Luke's-Roosevelt Hospital Center
 2004-11 PHASE4
NCT00611975 COMPLETED
Healthy
Weill Medical College of Cornell University
 2005-10 PHASE4
NCT00534001 COMPLETED
Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder
Roswell Park Cancer Institute
 2006-01 PHASE2
NCT00625859 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2008-01-16 PHASE1
NCT00086411 COMPLETED
Tobacco Use Disorder
University of Pennsylvania
 2003-09 PHASE2
NCT00296517 COMPLETED
Depressive Disorder
GlaxoSmithKline
 2006-01-19 PHASE3
NCT03927950 COMPLETED
Major Depression
University of Tartu
 2007-01 PHASE4
NCT00770666 COMPLETED
Smoking Cessation
University of Medicine and Dentistry of New Jersey
 2005-09 PHASE4
NCT00330616 COMPLETED
Major Depressive Disorder (MDD)
GlaxoSmithKline
 2006-05 PHASE2
NCT00318409 COMPLETED
Substance Abuse; HIV Infections
San Francisco Department of Public Health
 2006-09 PHASE2
NCT00267813 COMPLETED
Nicotine Dependence
Tel-Aviv Sourasky Medical Center
 2004-07
NCT01576640 TERMINATED
Nicotine Dependence; Schizophrenia
Massachusetts General Hospital
 2005-12 PHASE4
NCT00186446 COMPLETED
Major Depressive Disorder; Nicotine Dependence
Stanford University
 2004-06 PHASE4
NCT00248118 TERMINATED
Tobacco Dependence
National Institute on Drug Abuse (NIDA)
 2005-01 PHASE2; PHASE3
NCT00339014 COMPLETED
Obesity
Orexigen Therapeutics, Inc
 2006-05 PHASE2
NCT00135512 COMPLETED
Depressive Disorder
GlaxoSmithKline
 2004-12-01 PHASE2
NCT00296777 COMPLETED
Major Depression; Dysthymia
New York State Psychiatric Institute
 2004-12 PHASE4
NCT00135785 COMPLETED
Methamphetamine
National Institute on Drug Abuse (NIDA)
 2005-10 PHASE2
NCT00248209 COMPLETED
Orgasmic Disorder
Segraves, R., T., M.D., Ph.D.
 2004-05 PHASE2; PHASE3
NCT00364871 COMPLETED
Obesity
Orexigen Therapeutics, Inc
 2005-04 PHASE2
NCT00181896 TERMINATED
Depression; Bipolar Disorder
Massachusetts General Hospital
 2005-01 PHASE4
NCT00218231 COMPLETED
Schizophrenia; Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)
 2004-01 PHASE2
NCT00142831 COMPLETED
Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)
 1999-04 PHASE4
NCT00261170 COMPLETED
Smoking
University of California, San Francisco
 2003-07 PHASE3
NCT00296712 COMPLETED
Major Depression; Dysthymia; Depression NOS
New York State Psychiatric Institute
 2005-02 PHASE4
NCT00063323 COMPLETED
Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)
 2000-08 PHASE3
NCT00033592 COMPLETED
Lung Cancer
Alliance for Clinical Trials in Oncology
 2002-02 PHASE3
NCT00593099 COMPLETED
Bipolar Disorder
National Institute on Drug Abuse (NIDA)
 2004-04 PHASE1; PHASE2
NCT00142870 COMPLETED
Marijuana Abuse; Substance-Related Disorders
National Institute on Drug Abuse (NIDA)
 2005-03 PHASE2
NCT00865111 COMPLETED
Healthy
Actavis Inc.
 2006-03 PHASE1
NCT00126373 COMPLETED
Crohn Disease
Altschuler, Eric, M.D.
 2005-05 PHASE2; PHASE3
NCT03920319 COMPLETED
Smoking; Smoking, Tobacco
University of California, Los Angeles
 2004-01-01 PHASE1
NCT00176449 COMPLETED
Tobacco Use Disorder
University of Maryland, Baltimore
 2001-04 PHASE4
NCT00227812 COMPLETED
Cocaine Dependence; Depressive Disorder, Major
National Institute on Drug Abuse (NIDA)
 2001-04 PHASE2
NCT00093288 COMPLETED
Depressive Disorder, Major
GlaxoSmithKline
 2004-06 PHASE3
NCT00864981 COMPLETED
Depression
Sandoz
 2005-09 PHASE1
NCT00055393 COMPLETED
Pathological Gambling
University of Iowa
 2002-07
NCT00414180 COMPLETED
Smokeless Tobacco
Mayo Clinic
 2003-08 PHASE3
NCT00064467 COMPLETED
Epilepsy; Major Depressive Disorder (MDD)
GlaxoSmithKline
 2003-06 PHASE3
NCT00316160 COMPLETED
Depressive Disorder, Major; Major Depressive Disorder (MDD)
GlaxoSmithKline
 2004-09 PHASE4
NCT00044434 COMPLETED
Alcoholism; Smoking
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 2002-05 PHASE4
NCT00218218 COMPLETED
Schizophrenia and Disorders With Psychotic Features; Tobacco Use Disorder; Schizophrenia
National Institute on Drug Abuse (NIDA)
 2002-06 PHASE2
NCT00087880 COMPLETED
Tobacco Use Disorder
National Institute on Drug Abuse (NIDA)
 2002-12 PHASE2
NCT00061087 COMPLETED
ADHD; Opioid-Related Disorders; Cocaine Dependence
New York State Psychiatric Institute
 1998-02 PHASE2; PHASE3
NCT00104598 COMPLETED
Tobacco Use Disorder
Yale University
 2000-09
NCT00249509 COMPLETED
Marijuana Abuse
National Institute on Drug Abuse (NIDA)
 2000-09 PHASE2
NCT00865410 COMPLETED
Healthy
Actavis Inc.
 2004-08 PHASE1
NCT00865371 COMPLETED
Healthy
Actavis Inc.
 2004-09 PHASE1
NCT00863941 COMPLETED
Healthy
Actavis Inc.
 2004-06 PHASE1
NCT00865462 COMPLETED
Healthy
Actavis Inc.
 2004-07 PHASE1
NCT00069459 COMPLETED
Depressive Disorder
GlaxoSmithKline
 2003-09-23 PHASE1
NCT00051259 COMPLETED
Major Depressive Disorder (MDD)
GlaxoSmithKline
 2003-01 PHASE3
NCT00051272 COMPLETED
Major Depressive Disorder (MDD)
GlaxoSmithKline
 2003-01 PHASE3
NCT00861939 COMPLETED
Depression
Sandoz
 2004-03 PHASE1
NCT00285584 COMPLETED
HIV Infections; Depression
NYU Langone Health
 2002-09 PHASE1
NCT00032084 TERMINATED
Lung Cancer
SWOG Cancer Research Network
 2002-01 PHASE3
NCT00307203 COMPLETED
Tobacco-Use Disorder; Schizophrenia; Psychotic Disorders
National Institute on Drug Abuse (NIDA)
 1998-08 PHASE4
NCT01875172 COMPLETED
Smoking Cessation; Pregnancy
Watching Over Mothers & Babies Foundation
 2001-10 PHASE2
NCT00048360 COMPLETED
Attention Deficit Disorder
GlaxoSmithKline
 2002-10 PHASE3
NCT00046241 COMPLETED
Seasonal Affective Disorder
GlaxoSmithKline
 2002-09 PHASE3
NCT00628225 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
ZonMw: The Netherlands Organisation for Health Research and Development
 2000-03 PHASE4
NCT01621009 COMPLETED
Tobacco Dependence; Smoking
University of Wisconsin, Madison
 2001-01 PHASE4
NCT01621022 COMPLETED
Tobacco Dependence
University of Wisconsin, Madison
 2001-01 PHASE4
NCT00000457 COMPLETED
Alcoholism; Smoking
Mayo Clinic
 1998-06 PHASE2
NCT01270555 COMPLETED
Attention Deficit Hyperactivity Disorder (ADHD); Substance Use Disorder (SUD)
Massachusetts General Hospital
 1999-05
NCT00000276 TERMINATED
Cocaine-Related Disorders
Yale University
 1994-09 PHASE1
NCT00883155 COMPLETED
Healthy
Sandoz
 1998-10 PHASE1
NCT00236288 COMPLETED
Cancer and Tobacco Abuse
Indiana University
 2005-10
NCT00133757 COMPLETED
Nicotine Dependence; Tobacco Dependence
Centre for Addiction and Mental Health
 2005-06 PHASE1
NCT00484692 COMPLETED
Nicotine Dependence; Substance Abuse; Substance Dependence; Tobacco Dependence
Medical University Innsbruck
 2005-07 PHASE4
NCT00012558 COMPLETED
Bipolar Disorder
National Institute of Mental Health (NIMH)
 1998-09
NCT00296933 COMPLETED
Depression; Major Depressive Disorder
University Health Network, Toronto
 2005-12 PHASE3
NCT00344695 COMPLETED
Nicotine Dependence
University of Arizona
 PHASE3
NCT00124683 COMPLETED
Tobacco Use Cessation; Tobacco Use Disorder; Schizophrenia
National Institute on Drug Abuse (NIDA)
 2001-09 PHASE2
NCT00495352 COMPLETED
Tobacco Dependence; Schizophrenia
Yu-Li Hospital
 2006-01 PHASE4
NCT01048983 WITHDRAWN
Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
 PHASE1; PHASE2
NCT00080158 COMPLETED
Depression; Suicide, Attempted
New York State Psychiatric Institute
 2004-03 PHASE2; PHASE3
NCT00125905 UNKNOWN
Smoking Cessation
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
 2003-10
NCT01046214 TERMINATED
Depressive Disorder
Teva Pharmaceuticals USA
 2010-01 PHASE1
NCT00001483 COMPLETED
Bipolar Disorder; Depressive Disorder
National Institute of Mental Health (NIMH)
 1995-06 PHASE2
NCT00119210 TERMINATED
Tobacco Use Disorder
Massachusetts General Hospital
 2005-03 PHASE4
NCT00177567 COMPLETED
Bipolar Disorder
University of Pittsburgh
 2001-07 PHASE4
NCT00285155 COMPLETED
Healthy
University Hospital, Montpellier
 2004-11
NCT00000268 COMPLETED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 1995-05
NCT00181818 COMPLETED
Smoking; Myocardial Infarction; Unstable Angina; Cardiovascular Disease
Massachusetts General Hospital
 1999-10 PHASE4
NCT00320723 COMPLETED
Schizophrenia; Schizoaffective Disorder
North Suffolk Mental Health Association
 2001-07 PHASE4
NCT00069251 COMPLETED
Amphetamine-Related Disorders
National Institute on Drug Abuse (NIDA)
 2003-07 PHASE2
NCT00018187 COMPLETED
Smoking
US Department of Veterans Affairs
 1998-11 PHASE1
NCT00108537 COMPLETED
Tobacco Use Disorder
US Department of Veterans Affairs
 2003-10 PHASE3
NCT00079469 COMPLETED
Cancer Survivor; Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC)
 2004-02
NCT00351910 COMPLETED
Major Depressive Disorder
AstraZeneca
 2006-05 PHASE3
NCT00040040 UNKNOWN
Amphetamine-Related Disorders
National Institute on Drug Abuse (NIDA)
 2002-06 PHASE1
NCT00205946 COMPLETED
Major Depressive Disorder
Affective Neuroscience Laboratory
 2005-04 PHASE1
NCT00930306 COMPLETED
Chronic Pain
AstraZeneca
 2009-06 PHASE1
NCT00129246 COMPLETED
Smoking; Nicotine Dependence
Yale University
 2004-12 PHASE1; PHASE2
NCT00179244 COMPLETED
Unipolar Depression
Vanderbilt University
 2004-07 PHASE3
NCT00234195 COMPLETED
Breast Cancer; Major Depressive Disorder
Thomas Jefferson University
 2005-09 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-07-08)

Check the Amfebutamone (Bupropion) HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Amfebutamone (Bupropion) hydrochloride selectively binds to dopamine and norepinephrine transporters, with IC50 values of 6.5 μM and 3.4 μM respectively, while also functioning as a nicotinic acetylcholine receptor antagonist to block presynaptic monoamine reuptake. This inhibition increases synaptic concentrations of dopamine and norepinephrine to modulate central neurotransmission and reward pathways, providing therapeutic efficacy in clinical conditions such as major depressive disorder, obesity, and tobacco use disorder.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.